Barbara Sleight
- Hematology top 2%
- Chronic Myeloid Leukemia Treatments 6
- Acute Myeloid Leukemia Research 3
- Oncology top 5%
- CAR-T cell therapy research 12
- HER2/EGFR in Cancer Research 2
-
- Acute Lymphoblastic Leukemia research 15
-
- Lymphoma Diagnosis and Treatment 4
-
- Chronic Lymphocytic Leukemia Research 4
-
- Hedgehog Signaling Pathway Studies 2
- Co-authors
- Erik VandendriesMatthias StelljesAnjali S. AdvaniDaniel J. DeAngeloHagop M. KantarjianSusan O’BrienWendy StockMichaela Liedtke
- Partner nations
- United StatesGermanyItaly
In The Last Decade
Barbara Sleight
23 papers receiving 1.4k citations
Hit Papers
Peers
Comparison fields: 5 of 70
- Hematology 618
- Oncology 874
- Public Health, Environmental and Occupational Health 879
- Pathology and Forensic Medicine 270
- Pediatrics, Perinatology and Child Health 226
Countries citing papers authored by Barbara Sleight
This map shows the geographic impact of Barbara Sleight's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Sleight with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Sleight more than expected).
Fields of papers citing papers by Barbara Sleight
This network shows the impact of papers produced by Barbara Sleight. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Sleight. The network helps show where Barbara Sleight may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Barbara Sleight, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 29 | |
| 2 | 2019 | 38 | |
| 3 | 2019 | 8 | |
| 4 | 2019 | 12 | |
| 5 | 2019 | 7 | |
| 6 | 2019 | 224 | |
| 7 | 2018 | 44 | |
| 8 | 2018 | 3 | |
| 9 | 2018 | 5 | |
| 10 | 2017 | 5 | |
| 11 | 2017 | 138 | |
| 12 | Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemiabreakdown → | 2016 | 869 |
| 13 | 2016 | 2 | |
| 14 | 2016 | 6 | |
| 15 | 2012 | 1 | |
| 16 | 2012 | 13 | |
| 17 | 2011 | 15 | |
| 18 | 1999 | 7 | |
| 19 | 1998 | 20 | |
| 20 | S-cells from a highly N-myc-amplified neuroblastoma are tumorigenic in nude mice. | 1994 | 2 |
About Barbara Sleight
Barbara Sleight is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Oncology, having authored 23 papers that have together received 1.5k indexed citations. Recurring topics across this work include Acute Lymphoblastic Leukemia research (15 papers), CAR-T cell therapy research (12 papers), Chronic Myeloid Leukemia Treatments (6 papers), Chronic Lymphocytic Leukemia Research (4 papers), Lymphoma Diagnosis and Treatment (4 papers), Acute Myeloid Leukemia Research (3 papers), Hedgehog Signaling Pathway Studies (2 papers) and HER2/EGFR in Cancer Research (2 papers). The work is most often cited by research in Hematology (618 citations), Oncology (874 citations) and Public Health, Environmental and Occupational Health (879 citations). Barbara Sleight has collaborated with scholars based in United States, Germany and Italy. Frequent co-authors include Erik Vandendries, Matthias Stelljes, Anjali S. Advani, Daniel J. DeAngelo, Hagop M. Kantarjian, Susan O’Brien, Wendy Stock, Michaela Liedtke, Nicola Gökbuget and Tao Wang. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cancer, Clinical Cancer Research and Future Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.